Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis

Santa Mammana, Placido Bramanti, Emanuela Mazzon, Eugenio Cavalli, Maria Sofia Basile, Paolo Fagone, Maria Cristina Petralia, James Andrew McCubrey, Ferdinando Nicoletti, Katia Mangano

Research output: Contribution to journalArticle

Abstract

The PI3K/AKT/mTOR pathway is an intracellular signalling pathway that regulates cell activation. proliferation, metabolism and apoptosis. Increasing body of data suggests that alterations in the PI3K/AKT/mTOR pathway may result in an enhanced susceptibility to autoimmunity. Multiple Sclerosis (MS) is one of the most common chronic inflammatory diseases of the central nervous system leading to demyelination and neurodegeneration. In the current study, we have firstly evaluated in silico the involvement of the mTOR network on the generation and progression of MS and on oligodendrocyte function, making use of currently available whole-genome transcriptomic data. Then, the data generated in silico were subjected to an ex-vivo evaluation. To this aim, the involvement of mTOR was validated on a well-known animal model of MS and in vitro on Th17 cells. Our data indicate that there is a significant involvement of the mTOR network in the etiopathogenesis of MS and that Rapamycin treatment may represent a useful therapeutic approach in this clinical setting. On the other hand, our data showed that a significant involvement of the mTOR network could be observed only in the early phases of oligodendrocyte maturation, but not in the maturation process of adult oligodendrocytes and in the process of remyelination following demyelinating injury. Overall, our study suggests that targeting the PI3K/mTOR pathway, although it may not be a useful therapeutic approach to promote remyelination in MS patients, it can be exploited to exert immunomodulation, preventing/delaying relapses, and to treat MS patients in order to slow down the progression of disability.

Original languageEnglish
Pages (from-to)8263-8277
Number of pages15
JournalOncotarget
Volume9
Issue number9
DOIs
Publication statusPublished - Feb 2 2018

Fingerprint

Phosphatidylinositol 3-Kinases
Multiple Sclerosis
Animal Models
Oligodendroglia
Computer Simulation
Th17 Cells
Immunomodulation
Demyelinating Diseases
Sirolimus
Autoimmunity
Chronic Disease
Therapeutics
Central Nervous System
Genome
Apoptosis
Recurrence
Wounds and Injuries

Cite this

Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. / Mammana, Santa; Bramanti, Placido; Mazzon, Emanuela; Cavalli, Eugenio; Basile, Maria Sofia; Fagone, Paolo; Petralia, Maria Cristina; McCubrey, James Andrew; Nicoletti, Ferdinando; Mangano, Katia.

In: Oncotarget, Vol. 9, No. 9, 02.02.2018, p. 8263-8277.

Research output: Contribution to journalArticle

Mammana, S, Bramanti, P, Mazzon, E, Cavalli, E, Basile, MS, Fagone, P, Petralia, MC, McCubrey, JA, Nicoletti, F & Mangano, K 2018, 'Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis', Oncotarget, vol. 9, no. 9, pp. 8263-8277. https://doi.org/10.18632/oncotarget.23862
Mammana, Santa ; Bramanti, Placido ; Mazzon, Emanuela ; Cavalli, Eugenio ; Basile, Maria Sofia ; Fagone, Paolo ; Petralia, Maria Cristina ; McCubrey, James Andrew ; Nicoletti, Ferdinando ; Mangano, Katia. / Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. In: Oncotarget. 2018 ; Vol. 9, No. 9. pp. 8263-8277.
@article{ba95e2f56bb3484cab4077997df49c17,
title = "Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis",
abstract = "The PI3K/AKT/mTOR pathway is an intracellular signalling pathway that regulates cell activation. proliferation, metabolism and apoptosis. Increasing body of data suggests that alterations in the PI3K/AKT/mTOR pathway may result in an enhanced susceptibility to autoimmunity. Multiple Sclerosis (MS) is one of the most common chronic inflammatory diseases of the central nervous system leading to demyelination and neurodegeneration. In the current study, we have firstly evaluated in silico the involvement of the mTOR network on the generation and progression of MS and on oligodendrocyte function, making use of currently available whole-genome transcriptomic data. Then, the data generated in silico were subjected to an ex-vivo evaluation. To this aim, the involvement of mTOR was validated on a well-known animal model of MS and in vitro on Th17 cells. Our data indicate that there is a significant involvement of the mTOR network in the etiopathogenesis of MS and that Rapamycin treatment may represent a useful therapeutic approach in this clinical setting. On the other hand, our data showed that a significant involvement of the mTOR network could be observed only in the early phases of oligodendrocyte maturation, but not in the maturation process of adult oligodendrocytes and in the process of remyelination following demyelinating injury. Overall, our study suggests that targeting the PI3K/mTOR pathway, although it may not be a useful therapeutic approach to promote remyelination in MS patients, it can be exploited to exert immunomodulation, preventing/delaying relapses, and to treat MS patients in order to slow down the progression of disability.",
author = "Santa Mammana and Placido Bramanti and Emanuela Mazzon and Eugenio Cavalli and Basile, {Maria Sofia} and Paolo Fagone and Petralia, {Maria Cristina} and McCubrey, {James Andrew} and Ferdinando Nicoletti and Katia Mangano",
year = "2018",
month = "2",
day = "2",
doi = "10.18632/oncotarget.23862",
language = "English",
volume = "9",
pages = "8263--8277",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "9",

}

TY - JOUR

T1 - Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis

AU - Mammana, Santa

AU - Bramanti, Placido

AU - Mazzon, Emanuela

AU - Cavalli, Eugenio

AU - Basile, Maria Sofia

AU - Fagone, Paolo

AU - Petralia, Maria Cristina

AU - McCubrey, James Andrew

AU - Nicoletti, Ferdinando

AU - Mangano, Katia

PY - 2018/2/2

Y1 - 2018/2/2

N2 - The PI3K/AKT/mTOR pathway is an intracellular signalling pathway that regulates cell activation. proliferation, metabolism and apoptosis. Increasing body of data suggests that alterations in the PI3K/AKT/mTOR pathway may result in an enhanced susceptibility to autoimmunity. Multiple Sclerosis (MS) is one of the most common chronic inflammatory diseases of the central nervous system leading to demyelination and neurodegeneration. In the current study, we have firstly evaluated in silico the involvement of the mTOR network on the generation and progression of MS and on oligodendrocyte function, making use of currently available whole-genome transcriptomic data. Then, the data generated in silico were subjected to an ex-vivo evaluation. To this aim, the involvement of mTOR was validated on a well-known animal model of MS and in vitro on Th17 cells. Our data indicate that there is a significant involvement of the mTOR network in the etiopathogenesis of MS and that Rapamycin treatment may represent a useful therapeutic approach in this clinical setting. On the other hand, our data showed that a significant involvement of the mTOR network could be observed only in the early phases of oligodendrocyte maturation, but not in the maturation process of adult oligodendrocytes and in the process of remyelination following demyelinating injury. Overall, our study suggests that targeting the PI3K/mTOR pathway, although it may not be a useful therapeutic approach to promote remyelination in MS patients, it can be exploited to exert immunomodulation, preventing/delaying relapses, and to treat MS patients in order to slow down the progression of disability.

AB - The PI3K/AKT/mTOR pathway is an intracellular signalling pathway that regulates cell activation. proliferation, metabolism and apoptosis. Increasing body of data suggests that alterations in the PI3K/AKT/mTOR pathway may result in an enhanced susceptibility to autoimmunity. Multiple Sclerosis (MS) is one of the most common chronic inflammatory diseases of the central nervous system leading to demyelination and neurodegeneration. In the current study, we have firstly evaluated in silico the involvement of the mTOR network on the generation and progression of MS and on oligodendrocyte function, making use of currently available whole-genome transcriptomic data. Then, the data generated in silico were subjected to an ex-vivo evaluation. To this aim, the involvement of mTOR was validated on a well-known animal model of MS and in vitro on Th17 cells. Our data indicate that there is a significant involvement of the mTOR network in the etiopathogenesis of MS and that Rapamycin treatment may represent a useful therapeutic approach in this clinical setting. On the other hand, our data showed that a significant involvement of the mTOR network could be observed only in the early phases of oligodendrocyte maturation, but not in the maturation process of adult oligodendrocytes and in the process of remyelination following demyelinating injury. Overall, our study suggests that targeting the PI3K/mTOR pathway, although it may not be a useful therapeutic approach to promote remyelination in MS patients, it can be exploited to exert immunomodulation, preventing/delaying relapses, and to treat MS patients in order to slow down the progression of disability.

U2 - 10.18632/oncotarget.23862

DO - 10.18632/oncotarget.23862

M3 - Article

VL - 9

SP - 8263

EP - 8277

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 9

ER -